Humacyte, Inc. (HUMAW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jul 27Jul 30Aug 4Aug 7Aug 12Aug 17Aug 20Aug 25

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

Market Cap

$142481.96

MomentumView details →

1D Return

−78.05%

YTD Return

−99.04%

RSI (14)

32.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

Market Cap

$142481.96

RSI (14)

32.4

MomentumView details →

1D Return

−78.05%

YTD Return

−99.04%

ProfitabilityView details →

Gross Margin

−666.81%

Net Margin

−4560.82%

EBITDA Margin

−3755.68%

ROE (TTM)

−309.44%

ROA (TTM)

−70.05%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

−73.64%

EPS YoY

−13.11%

FCF YoY

—

Revenue CAGR 3Y

+9.20%

EPS CAGR 3Y

+79.37%

EBITDA YoY

−94.96%

EarningsView details →

EPS (Actual)

−$0.16

EPS Surprise

−41.04%

Beats (12Q)

3/12

Next Q EPS Est

−$0.09

Avg Surprise (4Q)

2.30%

Rev Surprise

−60.96%

Capital & dividendView details →

Debt/Equity

2.12x

Current Ratio

6.21x

Quick Ratio

5.74x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

2.12M

Net Income (TTM)

−96.73M

Op. CF (TTM)

−97.19M

Next earningsNov 6, 2026 →

Latest newsMore news →

Humacyte, Inc. reported Q2 2026 revenue of $0.4 million and a net loss of $36.8 million, with diluted EPS of -$0.16.24d ago

Humacyte, Inc. (HUMA) shares rose 2.33% to close at $0.73 in the recent trading session.30d ago

Similar companies

Altamira Therapeutics Ltd.CYTO OSR Holdings, Inc.OSRHW Jasper Therapeutics, Inc.JSPRW SAB Biotherapeutics, Inc.SABSW Instinct Bio Technical Company Holdings Inc. WarrantsBIOTW Vincerx Pharma, Inc.VINC Find similar companies →

Latest newsMore news →

Humacyte, Inc. reported Q2 2026 revenue of $0.4 million and a net loss of $36.8 million, with diluted EPS of -$0.16.24d ago Humacyte, Inc. (HUMA) shares rose 2.33% to close at $0.73 in the recent trading session.30d ago Humacyte announced that the FDA accepted its IND application for a first-in-human clinical study of CTEV for coronary artery bypass grafting.40d ago